- Meeting abstract
- Open Access
The effect of natriuretic peptides and bradykinin on development of brain oedema after ischemic stroke
© Dobrivojević et al. 2015
Published: 2 September 2015
Ischemic stroke is characterized by a rapid loss of brain function due to disturbance in blood supply to a part of the brain. Due to fixed intracranial space, any increase in intracranial fluid volume, or progressive brain oedema formation, contributes to further deterioration of the already impaired brain function. Bradykinin (BK), which levels increase during ischemic stroke, promotes blood–brain barrier permeability and raises intracranial capillary blood pressure, leading to brain oedema formation. Furthermore, BK induces glutamate release from neurons and astrocytes via activation of BK receptor type 2. suggesting involvement of BK in glutamate neurotoxicity. It has been recently shown that humans without functional natriuretic peptides (NPs) suffer from massive stokes [1, 2].
NPs can reduce brain oedema and have a neuroprotective role in acute ischemic stroke as well as during recovery after stroke. Although mechanisms are still not clear, it appears that NPs enhance angiogenesis, neurogenesis and oligodenrogenesis [3, 4]. One of the possible beneficiary effects of NPs during the stroke could be an inhibition of BK pathological function.
Materials and methods
Aim of our study is to determine beneficial effects of the NPs in stroke development in murine model (middle cerebral artery occlusion – MCAO). The symptoms of the stroke are determined by behavioural studies. The sizes of the lesion and brain oedema are established by μCT. Furthermore, we determined the effects of NPs on the BK signalling pathway in primary culture of neurons and astrocytes using whole cell patch clamp experiments to measure membrane potential and measurements of intracellular Ca2+ concentration.
In primary isolated astrocytes and neurons, BK binding to type 2 receptor, leads to an increase in intracellular C2+ concentration of astrocytes and neurons, followed by activation of Ca2+-dependent Cl- channel which depolarized the cell membrane. Agonists of guanylate cyclase A, partially guanylate cyclase C but not guanylate cyclase B inhibited the effects of BK at the membrane potential and intracellular Ca2+ concentration via regulators of G protein signalling. In vivo experiments showed that urodilatin inhibited development of stroke symptoms, the formation of the ischemic lesion and brain oedema.
The results of this research show the existence of a natural antagonist of the BK receptor type 2 in the mouse brain, and the possible use of NPs in treatment of the stroke.
This study is financed by the National Foundation for Science, Higher Education and Technological Development of the Republic of Croatia and EU-FP7-REGPOT–2012–CT2012–316120 GlowBrain project. Especially we would like to thank Prof. Dr. sc. Ines Drenjančević for providing access to her surgical equipment and setting up the Laser Doppler technique.
- Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, et al: Atrial Natriuretic Peptide Gene Polymorphisms and Risk of Ischemic Stroke in Humans. Stroke. 2004, 35 (4): 814-818. 10.1161/01.STR.0000119381.52589.AB.View ArticlePubMedGoogle Scholar
- Rubattu S, Ridker PM, Stampfer M, et al: The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation. 1999, 100: 1722-1726. 10.1161/01.CIR.100.16.1722.View ArticlePubMedGoogle Scholar
- Chen XM, Wang NN, Zhang TY, et al: Neuroprotection by Sildenafil: Neuronal Networks Potentiation in Acute Experimental Stroke. CNS Neurosci Ther. 2014, 20 (1): 40-49. 10.1111/cns.12162.View ArticlePubMedGoogle Scholar
- Zhang RL, Zhang ZG, Chopp M: Targeting nitric oxide in the subacute restorative treatment of ischemic stroke. Expert Opin Investig Drugs. 2013, 22 (7): 843-851. 10.1517/13543784.2013.793672.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.